EXPAREL Provides Pain Relief When It Matters Most
EXPAREL in Oral/Maxillofacial Surgery
Patients Fear Dental Pain—But Opioids Aren’t The Answer
1 Out of 3 Americans Avoids the Dentist Due to Dental Fear1*
What patients fear most is pain
70% of Patients
are prescribed opioids for postsurgical pain after a third molar extraction2
They also fear opioids because of the related risks
33% Increased Risk
of future opioid use in patients prescribed opioids legitimately in 12th grade3
With EXPAREL, You Can Make Patients Comfortable With Less Reliance On Opioids
Non-opioid EXPAREL is a proven, long-lasting anesthetic that controls pain for the first few days after surgery—when your patients need relief most. In third molar extraction, dental implants, and orthognathic and craniofacial procedures, opioid-sparing EXPAREL consistently demonstrates4-7:
Less Need for Opioids
Third molar extraction4‡
- 59% reduction in total prescribed opioids in MMEs4; 47.1 vs 113.8 MMEs; rate ratio, 0.41 (0.39–0.44) (P<0.0001)
- 57% reduction in opioid prescription refill rate; 3.3% vs 7.7% (P=0.028)
Less Pain
Craniofacial procedures5§
- 97% reduction in pain scores in the first 4 hours of the postsurgical period 0.1 ± 0.5 (SD) vs 3.7 ± 3.5 (SD) (P<0.001)
- Significant reduction in pain scores in the first 24 hours of the postsurgical period; 12 (P=0.010), 16 (P=0.002), 20 (P=0.006), and 24 (P=0.009) hours
*According to a 2018 global survey by DentaVox
†The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials
‡Results from a retrospective cross-sectional analysis of patients undergoing third molar extraction (N=600) receiving local infiltration with EXPAREL (n=300) compared with patients who did not receive EXPAREL (n=300)4
§Results from a retrospective cohort study of patients undergoing alveolar bone grafting with an open iliac crest bone harvest (N=38) receiving EXPAREL at the hip donor site (n=17) compared with patients receiving bupivacaine HCl at the hip donor site (n=21)5
MME, morphine milligram equivalent.
Societies Recommend Opioid-Minimizing Pain Management Platforms
Leading medical societies recommend opioid-minimizing pain management strategies to enhance recovery after oral and maxillofacial procedures
AAOMS
The oral and maxillofacial surgeon should avoid starting treatment with long-acting or extended-release opioid analgesics.8
AAOMS, American Association of Oral and Maxillofacial Surgeons.
Related Resources
